London, UK (PRWEB) April 09, 2015
Pharmacos are developing more effective drug delivery vehicles with the aid of nanotechnology. Lack of specificity induces undue drug wastage, reduced potency and undesirable side effects during treatment. This is a serious problem, especially when a patient is suffering from cancer, where the use of chemotherapy is part of therapeutic regimen. Easy modification, customisability and product cost are set to be the major factors determining the commercial success apart from their pharmacological benefits. Heavy investments in R&D are poised to assist in identifying effective nanoparticle-based drug delivery vehicles.
Manifold nanotechnology-based devices, medicines, chips and sensors are undergoing various stages of clinical trials. To date, there are 144 nanomedicines in clinical development. The majority of the nanomedicines are in pre-clinical development phase, followed by research phase. Only a limited number of products are in the market for few indications; currently, 13 nanomedicines are commercially available in the market. Their clinical pipeline is getting stronger year by year and novel incentives are being taken by pharmacos, but the rate of commercialisation of such products is slow and the market size is still limited. To surmount these barriers, the pace of R&D alongside market introduction needs to be increased in the offing. This would help generate a big chunk of revenues, however, it will take several years for nanomedicines to receive recognition as mainstream medicines. Judging by the pace at which they are growing, nanomedicines and associated medical technologies have bright future.
New research report “Global Nanomedicine Market & Pipeline Insight 2015” developed by Kuick Research is now available at MarketPublishers.com.
Title: Global Nanomedicine Market & Pipeline Insight 2015
Published: April, 2015
Price: US$ 2,400.00
The report offers a detailed guide to the worldwide nanomedicine (nanotherapeutic) marketplace. It provides deep insights into the nanomedicine mechanism, an analysis of the present-day market scenario and an overview of the nanomedicine product pipeline globally. The research report limelights the market dynamics covering major market driving factors and challenges, as well as peeps into the future development path of the sector. The study reviews the nanomedicine product clinical pipeline by indication, phase and company; discusses marketed nanomedicines by company and disease indication; sheds light on the suspended and discontinued nanomedicine clinical pipeline. The research publication delves in the competitive landscape along with profiling the major players.
- Comprehensive analysis of the world market for nanomedicines, their use in cancer treatments and mechanisms.
- In-depth review of the market dynamics, covering favourable factors and challenges.
- Insights into the global nanomedicine product clinical pipeline by company, indication and stage.
- Overview of the 144 nanomedicines in development stage.
- Discussion of the 13 marketed nanomedicines.
- Comprehensive patent analysis.
- All-round review of the competitive landscape in tandem with a discussion of the top 20 players.
- Global nanomedicine market future prospects.
More new reports by the publisher can be found at Kuick Research page.